LGNRF.PK

Leadrive Technology Completes Series C Financing, Legend Capital Re-upped

Retrieved on: 
Sunday, September 25, 2022
ESG, Trust, Health, Industry, USD, VC, CEO, IGBT, Technology, RMB, UNPRI, Silicon, R, Original equipment manufacturer, Renewable energy

HONG KONG, Sept 25, 2022 - (ACN Newswire) - Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing.

Key Points: 
  • HONG KONG, Sept 25, 2022 - (ACN Newswire) - Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing.
  • After five years of rapid development, Leadrive Technology is equipped with mature technology and product solutions in the power modules and motor control units.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Legend Capital: The Logic of Technology Investment Has Changed

Retrieved on: 
Friday, September 2, 2022
Technology, Venture capital, China concepts stock, WuXi Biologics, IFlytek, VC, TMT, Home, Health, STAR, Science, ChiNext, Map, Mission statement, Time, Japan Exchange Group, KOSDAQ, USD, Korea Exchange, History, London Stock Exchange Group, ESG, Industry, Specialization, CRO, New York Stock Exchange, Lithium, R, Judgement, Hong Kong Stock Exchange, Innovation, Investment, Pony.ai, Wuxi, Shenzhen Stock Exchange, Shanghai Stock Exchange, Taiwan Stock Exchange, Logic, Star Market, IPO, Architecture, Differentiation, Interview, Refinement, Radar, Environment, UNPRI, Initial public offering, CATL, Security (finance), Fine chemical, Renewable energy, Bank, Video game, Cryptocurrency, Nasdaq, RMB

In a recent interview, Richard Li, President of Legend Capital, revealed the history of Legend Capital in technology investment, and proposed that the logic of technology investment has undergone important changes.

Key Points: 
  • In a recent interview, Richard Li, President of Legend Capital, revealed the history of Legend Capital in technology investment, and proposed that the logic of technology investment has undergone important changes.
  • Richard Li, President of Legend Capital, said in the interview: "What matters is not about the quantity of IPOs, but more about the repeated verification of the investment expertise of Legend Capital team, who has long been rooted in technology investment.
  • Looking back at Legend Capital's development history, we can see a microcosm of the changes in China's technology investment.
  • So far, among Legend Capital's invested companies, there are over 100 unicorn companies with a valuation of over USD1 billion, creating a huge and systematic technology investment footprint.

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

Retrieved on: 
Friday, August 19, 2022
Map, Precision medicine, AI, Technology, CRO, VC, Research, Life, ESG, Mass spectrometry, Proteomics, CNY, RMB, Health, Biotechnology, UNPRI, Metabolomics, Big data, USD, Fine chemical

HONG KONG, Aug 19, 2022 - (ACN Newswire) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital.

Key Points: 
  • HONG KONG, Aug 19, 2022 - (ACN Newswire) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital.
  • Ms. CHEN Wei, the founder of APTBIO, said: "I would like to take this opportunity to extend my sincere gratitude to our investors.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

Retrieved on: 
Monday, August 15, 2022
ChiNext, Industry, R, CRO, Clinical trial, VC, Data management, ESG, WuXi AppTec, WuXi Biologics, D, RMB, Health, Series, UNPRI, Shenzhen Stock Exchange, USD, Fine chemical, Bellen

HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.

Key Points: 
  • HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.
  • Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies.
  • Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies!
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully

Retrieved on: 
Tuesday, August 9, 2022
Intellectual property, Investment, VC, ESG, Patient, WuXi Biologics, Infection, RMB, Star Market, Therapy, Health, UNPRI, Medication, USD, Pharmaceutical industry

HONG KONG, Aug 9, 2022 - (ACN Newswire) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market.

Key Points: 
  • HONG KONG, Aug 9, 2022 - (ACN Newswire) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market.
  • MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after the issuance.
  • Legend Capital invested in MicuRx Pharmaceuticals in 2020 and has long supported the company's development.
  • Legend Capital and the MicuRx team have established a deep friendship, and Legend Capital is honored to participate in the MicuRx business led by Dr. Zhengyu YUAN, the founder of MicuRx Pharmaceuticals.